Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02475395 · ClinicalTrials.gov registry record · NA

Study of the Consumer Use of a New Home Test to Measure Sperm Concentration

A NA study of Fertility, Male and Sub-Fertility, Male, sponsored by Sandstone Diagnostics.

Completed
Registry status
NA
Development phase
272
Enrollment target
3
Study locations

NCT02475395 is a NA study of Fertility, Male and Sub-Fertility, Male that has completed, run by Sandstone Diagnostics. The registered enrollment target is 272 participants. The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02475395, a NA study of Fertility, Male and Sub-Fertility, Male, has completed, sponsored by Sandstone Diagnostics.

COMPLETED
Registry status
NA
Development phase
272 participants
Enrollment target
3
Study locations

Study Summary

The objective of the study is to evaluate the agreement in measurement of sperm concentration in human semen between lay users with TRAK and a recognized reference method. The study will also include the measurement of matched samples by TRAK when tested by healthcare professionals trained in use of the TRAK device.

Interventions

  • DEVICE TRAK device

Study Locations (3)

California

  • California Reproductive Services: Huntington Reproductive Center - Encino
  • San Fernando Valley Urological Associates Medical Group - Tarzana

New York

  • Men's Fertility Laboratory - Great Neck

Trial Details

FieldValue
Enrollment Target 272 participants
Start Date 2015-09-02
Est. Completion 2015-11
Phase NA

Sponsor

Sandstone Diagnostics

1 total trials

What the Registry Record Tells You About NCT02475395

The ClinicalTrials.gov registry entry for NCT02475395 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sandstone Diagnostics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Fertility, Male appearing as the primary indexed condition, and to 1 intervention - of which TRAK device is the first listed.

NCT02475395 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, New York.

Frequently Asked Questions

What is clinical trial NCT02475395 about?

NCT02475395 is a clinical study titled "Study of the Consumer Use of a New Home Test to Measure Sperm Concentration". The objective of the study is to evaluate the agreement in measurement of sperm concentration in human semen between lay users with TRAK and a recognized reference method. The study will also include the measurement of matched samples by TRAK when tested by healthcare professionals trained in use of...

What is the current status of trial NCT02475395?

This trial is currently completed. It is a NA study. The enrollment target is 272 participants. The study started on 2015-09-02. Estimated completion is 2015-11.

What conditions does trial NCT02475395 study?

This clinical trial studies the following conditions: Fertility, Male, Sub-Fertility, Male.

What interventions are being tested in trial NCT02475395?

The interventions under investigation include: TRAK device (DEVICE).

Who is sponsoring clinical trial NCT02475395?

This trial is sponsored by Sandstone Diagnostics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02475395 being conducted?

This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.